Skip to main
BVS

Bioventus (BVS) Stock Forecast & Price Target

Bioventus (BVS) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Bioventus is an attractive investment opportunity for those seeking growth in the medical device industry. The company has a strong product portfolio with a focus on pain relief and musculoskeletal conditions. With a recent focus on investing in and commercializing their peripheral nerve stimulation business, Bioventus is positioned to see significant growth in the coming years. Additionally, the recent updates to CMS' fee schedule for bone growth stimulators and the company's strong financial performance and guidance make it a promising investment.

Bears say

Bioventus is facing several challenges that could impact its financial performance in the near future. These include a decrease in reimbursement rates for its products, particularly in the US, where it generates the majority of its revenues. This could limit the usage of its products and negatively impact its revenues. Additionally, the company operates in a highly competitive market with larger and well-established competitors, which could hinder its ability to grow and take market share. Moreover, the company is heavily dependent on regulatory approvals for its products, and any delay or hurdle in the regulatory process could significantly impact its operations and financial results. Given these challenges and the current valuation of the stock, the financial analyst maintains a negative outlook on Bioventus's stock.

Bioventus (BVS) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bioventus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bioventus (BVS) Forecast

Analysts have given Bioventus (BVS) a Buy based on their latest research and market trends.

According to 4 analysts, Bioventus (BVS) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bioventus (BVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.